title: In vitro anti-Toxoplasma gondii antibody production by peripheral blood mononuclear cells in the diagnosis and the monitoring of toxoplasmic encephalitis in AIDS-related brain lesions.
abstract: The spontaneous secretion in vitro of anti-Toxoplasma gondii antibodies by peripheral blood mononuclear cells was assessed in 69 patients with AIDS-related brain lesions. The sensitivity and specificity of this assay in the diagnosis of toxoplasmic encephalitis (TE) were found to be 85.4% and 92.8%, respectively. Twenty-four patients with TE were observed during 1-year follow-up after initiation of anti-Toxoplasma treatment and classified on the basis of their clinical and radiologic responses as sustained responders (SR; n = 11), incomplete responders (IR; n = 7) or transient responders (TR; n = 6). In vitro anti-T. gondii antibody secretion decreased as early as the first month after initiation of treatment and disappeared within the year in SRs, persisted in IRs, and decreased but rebounded at relapse in the TR patients. In vitro anti-T. gondii antibody, which reflects immune system activation by parasitic antigens, could be a surrogate marker of TE in AIDS patients.
authors: Centre National Recherche Scientifique, Laboratoire d'Immunologie des Infections Retrovirales, Institut de Biologie, Montpellier, France.
authors: C
authors: C
authors: Lacascade
authors: A M
authors: AM
authors: Conge
authors: V
authors: V
authors: Baillat
authors: I
authors: I
authors: Pages
authors: M F
authors: MF
authors: Huguet
authors: J
authors: J
authors: Reynes
authors: J P
authors: JP
authors: Vendrell
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000276:immunology*; D000328:Adult; D000368:Aged; D000913:Antibodies, Protozoan / Q000096:biosynthesis*; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D004660:Encephalitis / Q000175:diagnosis / Q000276:immunology*; D005602:France; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011739:Pyrimethamine / Q000627:therapeutic use; D012189:Retrospective Studies; D016781:Toxoplasmosis, Cerebral / Q000175:diagnosis / Q000276:immunology*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000913:Antibodies, Protozoan; D000981:Antiprotozoal Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D011739:Pyrimethamine